DK0428038T3 - Transdermal administration af 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazol - Google Patents

Transdermal administration af 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazol

Info

Publication number
DK0428038T3
DK0428038T3 DK90121170.6T DK90121170T DK0428038T3 DK 0428038 T3 DK0428038 T3 DK 0428038T3 DK 90121170 T DK90121170 T DK 90121170T DK 0428038 T3 DK0428038 T3 DK 0428038T3
Authority
DK
Denmark
Prior art keywords
tetrahydrobenzothiazole
propylamino
amino
transdermal administration
transdermal
Prior art date
Application number
DK90121170.6T
Other languages
English (en)
Inventor
Bernd Dr Zierenberg
Michael Dr Herschel
Uwe Dr Rohr
Original Assignee
Boehringer Ingelheim Int
Boehringer Ingelheim Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int, Boehringer Ingelheim Kg filed Critical Boehringer Ingelheim Int
Application granted granted Critical
Publication of DK0428038T3 publication Critical patent/DK0428038T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
DK90121170.6T 1989-11-09 1990-11-06 Transdermal administration af 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazol DK0428038T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3937271A DE3937271A1 (de) 1989-11-09 1989-11-09 Transdermale applikation von 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazol

Publications (1)

Publication Number Publication Date
DK0428038T3 true DK0428038T3 (da) 1994-08-29

Family

ID=6393163

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90121170.6T DK0428038T3 (da) 1989-11-09 1990-11-06 Transdermal administration af 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazol

Country Status (17)

Country Link
US (1) US5112842A (da)
EP (1) EP0428038B1 (da)
JP (1) JP3034588B2 (da)
KR (1) KR0184867B1 (da)
AT (1) ATE108668T1 (da)
AU (1) AU635358B2 (da)
CA (1) CA2029524C (da)
CZ (1) CZ277718B6 (da)
DE (2) DE3937271A1 (da)
DK (1) DK0428038T3 (da)
ES (1) ES2058725T3 (da)
FI (1) FI905531A7 (da)
HU (1) HU206043B (da)
IE (1) IE65564B1 (da)
IL (1) IL96276A (da)
NZ (1) NZ236002A (da)
ZA (1) ZA908953B (da)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3400649A1 (de) * 1984-01-11 1985-07-18 Jonny 4000 Düsseldorf Janus Fahrzeugrad
AU5596394A (en) * 1992-11-09 1994-06-08 Pharmetrix Corporation Transdermal delivery of ketorolac
US6486310B1 (en) * 1993-01-28 2002-11-26 Washington University Gene encoding the rat dopamine D4 receptor
US5650420A (en) * 1994-12-15 1997-07-22 Pharmacia & Upjohn Company Pramipexole as a neuroprotective agent
US6156777A (en) 1994-12-15 2000-12-05 Pharmacia & Upjohn Company Use of pramipexole as a neuroprotective agent
US6001861A (en) * 1998-01-16 1999-12-14 Pharmacia & Upjohn Company Use of pramipexole in the treatment of restless legs syndrome
DE19701619B4 (de) * 1997-01-17 2007-10-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Pramipexol zur Behandlung des restless legs syndroms
JP2009102351A (ja) * 1997-07-17 2009-05-14 Nitto Denko Corp 貼付剤
HUP0101803A3 (en) * 1998-05-15 2002-10-28 Upjohn Co New use of cabergoline and pramipexole for preparation of medicaments
AU760439B2 (en) * 1998-05-15 2003-05-15 Pharmacia & Upjohn Company Cabergoline and pramipexole: new uses and combinations
EP1591119A3 (en) * 1998-05-15 2007-03-28 Pharmacia & Upjohn Company LLC Pramipexole for treating CNS diseases, especially Parkinson's disease
DE19830201A1 (de) * 1998-07-07 2000-01-13 Boehringer Ingelheim Pharma Mittel mit antidepressiver Wirkung
DE19938825A1 (de) * 1999-08-19 2001-04-26 Boehringer Ingelheim Pharma Wirkstoffkombination mit Clonidin
PE20011074A1 (es) 2000-02-23 2001-10-04 Upjohn Co Uso de pramipexol en el tratamiento de trastornos de adiccion
WO2002011768A1 (en) * 2000-08-03 2002-02-14 Antares Pharma Ipl Ag Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
US20070225379A1 (en) * 2001-08-03 2007-09-27 Carrara Dario Norberto R Transdermal delivery of systemically active central nervous system drugs
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US7198801B2 (en) * 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
WO2005039531A1 (en) * 2003-10-10 2005-05-06 Antares Pharma Ipl Ag Transdermal pharmaceutical formulation for minimizing skin residues
DE10053397A1 (de) 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
WO2002069974A1 (en) * 2001-03-05 2002-09-12 Andrew Holman Administration of sleep restorative agents
DE10137162A1 (de) * 2001-07-30 2003-02-20 Hexal Ag Matrixkontrolliertes transdermales therapeutisches System zur Anwendung von Pramiprexol und Ropinirol
DE10138275A1 (de) * 2001-08-10 2003-02-27 Boehringer Ingelheim Pharma Verbindungen zur Beseitigung der Anhedonie
MXPA04005572A (es) 2001-12-11 2004-12-06 Univ Virginia Uso de pramipexol para tratamiento de esclerosis lateral amiotrofica.
US20060281797A1 (en) * 2001-12-11 2006-12-14 University Of Virginia Patent Foundation Neurorestoration with R(+) Pramipexole
DE10333393A1 (de) * 2003-07-23 2005-02-24 Lts Lohmann Therapie-Systeme Ag Transdermales Therapeutisches System mit dem Wirkstoff Pramipexol
WO2006125642A1 (en) 2005-05-27 2006-11-30 Antares Pharma Ipl Ag Methods and apparatus for transdermal or transmucosal application of testosterone
US20080234338A1 (en) * 2005-08-15 2008-09-25 University Of Virginia Patent Foundation Neurorestoration With R(+) Pramipexole
WO2007045620A1 (de) * 2005-10-18 2007-04-26 Boehringer Ingelheim International Gmbh Verwendung von pramipexol zur behandlung des moderaten bis schweren restless legs syndroms (rls)
ITMI20060044A1 (it) * 2006-01-13 2007-07-14 Dipharma Spa Sintesi di intermedi pr la preparazione di pramipexolo
US8518926B2 (en) * 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
US20070259930A1 (en) * 2006-04-10 2007-11-08 Knopp Neurosciences, Inc. Compositions and methods of using r(+) pramipexole
NZ571460A (en) 2006-04-21 2010-10-29 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
KR20090021169A (ko) * 2006-05-16 2009-02-27 크놉 뉴로사이언시스 인코포레이티드 Ｒ(+) 및 ｓ(-) 프라미펙솔을 포함하는 조성물 및 이의 사용 방법
WO2008001200A2 (en) * 2006-06-29 2008-01-03 Antares Pharma Ipl Ag Transdermal composition having enhanced color stability
WO2008001204A2 (en) * 2006-06-29 2008-01-03 Antares Pharma Ipl Ag Transdermal compositions of pramipexole having enhanced permeation properties
US20080254118A1 (en) * 2007-04-11 2008-10-16 Hans-Werner Wernersbach Process for preparing pramipexole dihydrochloride tablets
WO2008067991A2 (en) * 2006-12-08 2008-06-12 Antares Pharma Ipl Ag Skin-friendly drug complexes for transdermal administration
US8524695B2 (en) * 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
CN101715443A (zh) 2007-03-14 2010-05-26 诺普神经科学股份有限公司 手性纯化的取代的苯并噻唑二胺的合成
US20080254117A1 (en) * 2007-04-10 2008-10-16 Noel Cotton Process for preparing pramipexole dihydrochloride tablets
US20110190356A1 (en) * 2008-08-19 2011-08-04 Knopp Neurosciences Inc. Compositions and Methods of Using (R)- Pramipexole
CN102802418A (zh) * 2009-06-19 2012-11-28 诺普神经科学股份有限公司 用于治疗肌萎缩性侧索硬化的组合物和方法
KR101307334B1 (ko) * 2010-07-02 2013-09-12 주식회사 바이오파마티스 프라미펙솔 또는 이의 약학적으로 허용되는 염을 포함하는 안정성이 개선된 서방형 약학 조성물
WO2013096816A1 (en) 2011-12-22 2013-06-27 Biogen Idec Ma Inc. Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
DE102012205493A1 (de) 2012-04-03 2013-10-10 Acino Ag Einen Dopamin-Agonisten enthaltendes transdermales Applikationssystem
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
ES3043076T3 (en) 2013-07-12 2025-11-24 Areteia Therapeutics Inc Treating elevated levels of eosinophils and/or basophils
ES2871556T3 (es) 2013-08-13 2021-10-29 Knopp Biosciences Llc Composiciones y métodos para el tratamiento de la urticaria crónica
WO2015023786A1 (en) 2013-08-13 2015-02-19 Knopp Biosciences Llc Compositions and methods for treating plasma cell disorders and b-cell prolymphocytic disorders
WO2015129527A1 (ja) * 2014-02-27 2015-09-03 株式会社メドレックス プラミペキソールを含有する神経変性疾患の治療用貼付剤
EP3522843B1 (en) * 2016-10-07 2022-09-21 Transwell Biotech Co., Ltd. Pramipexole transdermal delivery system and uses thereof
PL3338768T3 (pl) 2016-12-20 2020-05-18 Lts Lohmann Therapie-Systeme Ag Transdermalny system terapeutyczny zawierający asenapinę
ES3001152T3 (es) 2016-12-20 2025-03-04 Lts Lohmann Therapie Systeme Ag Sistema terapéutico transdérmico que contiene asenapina y polisiloxano o poliisobutileno
WO2019002204A1 (en) 2017-06-26 2019-01-03 Lts Lohmann Therapie-Systeme Ag TRANSDERMAL THERAPEUTIC SYSTEM CONTAINING ASENAPINE AND SILICONE-TYPE ACRYLIC HYBRID POLYMER
CN111278425B (zh) 2017-09-11 2024-06-11 耶路撒冷希伯来大学伊萨姆研究开发有限公司 用于向脑部经鼻给药药物和用于全身作用的组合物和方法
EP3810099A1 (en) 2018-06-20 2021-04-28 LTS Lohmann Therapie-Systeme AG Transdermal therapeutic system containing asenapine
AU2019291060B2 (en) 2018-06-20 2024-09-05 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3572485D1 (en) * 1984-12-22 1989-09-28 Thomae Gmbh Dr K Tetrahydro-benzothiazoles, their production and their use as intermediates or drugs
US4826686A (en) * 1985-12-14 1989-05-02 Boehringer Ingelheim Kg Therapeutic system
US4826860A (en) * 1987-03-16 1989-05-02 Warner-Lambert Company Substituted 2-aminobenzothiazoles and derivatives useful as cerebrovascular agents

Also Published As

Publication number Publication date
IL96276A (en) 1994-11-28
US5112842A (en) 1992-05-12
CA2029524C (en) 2002-12-31
DE59006506D1 (de) 1994-08-25
NZ236002A (en) 1993-01-27
EP0428038A2 (de) 1991-05-22
FI905531A0 (fi) 1990-11-08
KR910009264A (ko) 1991-06-28
KR0184867B1 (ko) 1999-05-01
DE3937271A1 (de) 1991-05-16
FI905531A7 (fi) 1991-05-10
CZ277718B6 (en) 1993-03-17
HU206043B (en) 1992-08-28
EP0428038B1 (de) 1994-07-20
AU6650890A (en) 1991-05-16
JP3034588B2 (ja) 2000-04-17
AU635358B2 (en) 1993-03-18
ATE108668T1 (de) 1994-08-15
CA2029524A1 (en) 1991-05-10
CS553490A3 (en) 1992-04-15
HUT59005A (en) 1992-04-28
ES2058725T3 (es) 1994-11-01
IL96276A0 (en) 1991-08-16
IE65564B1 (en) 1995-11-01
EP0428038A3 (en) 1991-09-25
IE904021A1 (en) 1991-05-22
HU907065D0 (en) 1991-05-28
ZA908953B (en) 1992-07-29
JPH03170425A (ja) 1991-07-24

Similar Documents

Publication Publication Date Title
FI905531A0 (fi) Transdermalisk anvaendning av 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobensotiazol.
PT921812E (pt) Preparacoes de insulina contendo um halogenuro
DK0385279T3 (da) Biologisk aktive midler samt præparater og materialer, der indeholder de biologisk aktive midler
NO903527D0 (no) Laboratorieanordning, samt fremgangsmaate for behandling av steinproever.
DE69002520D1 (de) Azeotropaehnliche zusammensetzungen von 1,1-dichlor-2,2,2-trifluoraethan und 1,1-dochlor-1-fluoraethan.
NO860733L (no) N-(2-klor-4-trifluormethylfenyl)-3-trifluormethyl-benzensulfonamidderivat, fremgangsmaate for fremstilling av dette, og fungicid middel inneholdende dette.
NO901631D0 (no) Fremgangsmaate for fremstilling av 2-substituerte n,n'-ditrimetoksybenzoyl-piperaziner.
PT99061A (pt) Combinacoes de substancias activas do tipo piretroide, contendo benflutrin e pralletrin
DE69012298D1 (de) Heizen von Lagern und dergleichen.
NO904016L (no) Paafoerings-hjelpemiddel samt anvendelse av dette.
NO900564L (no) Overflateaktivt middel.
ATE25969T1 (de) 1,7-diphenyl-3-methylaza-7-cyan-8-methyl-nonan zur verwendung bei der bekaempfung von krankheiten.
DE69208681D1 (de) Verwendungen von 1,1,1,3,3,3-hexafluoropropan
FI874450A7 (fi) Farmaseuttiset valmisteet alkuperältään toiminnallisten ja elimelliste n aivohäiriöiden hoitamiseen.
DK632388A (da) Pharmaceutisk middel til behandling af hyperlipidaemi hol pattedyr
ES2061775T3 (es) Derivados de estrobirulina, su obtencion y empleo.
DE3670085D1 (de) 2-(1-hydroxy-2,2,6,6-tetraalkyl-piperidin-4-yloxy)-dibenzodioxaphosphepine und dibenzodioxaphosphocine.
DE3778104D1 (de) Zusammenstellung von hydroxylapatite-teilchen und diese enthaltende fluessigkeitschromatographie-saeule.
NO883987L (no) Fremgangsmaate for fremstilling av n-(substituert aklyliden) kondensert bicykloalkyliden og anvendelse derav som medikamenter.
KR900007413A (ko) 에이즈 발병방지, 치료제 및 그 치료용 조성물
FI890065A0 (fi) Foerfarande foer framstaellning av 5,8,13, 14-tetrahydrobenz/5,6/isoindolo/2,1-b/isokinolin-8,13-dionderivat.
IT8919204A0 (it) Composizione per la prevenzione e la cura di parodontopatte.
FI892952A7 (fi) Anordning foer automatisk plockning av produkter ur fack i lagerhylla.
ATE81454T1 (de) Acyl-carnitin zur behandlung und zur verhuetung von virusinfektionen.
ATE101194T1 (de) Azeotropaehnliche zusammensetzungen von 1,3dichlor-1,1,2,2,3-pentafluorpropan und 2-methyl-2-propanol.